News

All Blogs General News In the Media Information Investor Updates Publications

Latest 4C Report Highlights Emyria Collaborations

Jan 30, 2023

Latest 4C Report Highlights Emyria Collaborations

Dosing Commences on EMD-RX5 Phase 3 Clinical Trial

Jan 29, 2023

Dosing Commences on EMD-RX5 Phase 3 Clinical Trial

Emyria in the Australian Financial Review on the future of psychedelics

Jan 18, 2023

Emyria in the Australian Financial Review on the future of psychedelics

Emyria receives $2m+ R&D tax incentive refund

Jan 12, 2023

Emyria receives $2m+ R&D tax incentive refund

Blog: Looking at 2022 and forward into 2023

Dec 22, 2022

Blog: Looking at 2022 and forward into 2023

Watch the video – Planet Microcap Showcase Presentation

Dec 14, 2022

Watch the video – Planet Microcap Showcase Presentation

December 7 & 8 Webinars

Dec 06, 2022

December 7 & 8 Webinars

Emyria Company Update – December 2022

Dec 01, 2022

Emyria Company Update – December 2022

Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program

Nov 27, 2022

Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program

Load More